Complex forming compounds
SUBSTANCE: new formula (I) compounds are prepared, as well as their complexes, which can be used to prepare a pharmaceutical composition for prevention and treatment of strontium, tin or lead poisoning.
EFFECT: increased application effeciency.
13 cl, 9 tbl, 18 ex, 13 dwg
SUBSTANCE: invention relates to a polymer-based composition which contains a polyester and a cyclic carbodiimide. Disclosed is a polymer-based composition for moulded articles, which contains a polyester (component A), the terminal group of which is modified, and a compound which includes a cyclic structure with only one carbodiimide group, the first and second nitrogen atoms of which are bound together by a binding group in the cyclic structure (component B). The invention also discloses a method of producing said composition and an article moulded therefrom.
EFFECT: disclosed composition has no odour caused by free isocyanate.
26 cl, 1 tbl, 11 ex
SUBSTANCE: invention relates to novel 4-substituted-N-phenyl-1,8-naphthalimides which contain in the N-aryl nucleus a crown ether residue (with a different combination of oxygen, nitrogen and sulphur atoms) of general formula (I) , where R1=NO2, Br, NH2, OCH3, NHCOCH3, Ia: Rl=NO2, X=S, n=1; Ib: R1=NO2, x=NCH3, n=1; Ic: R1=NO2, X=NCH3, n=2; Id: R1=Br, X=NCH3, n=2; Ie: R1=NH2, X=S, n=1; If: R1=NHCOCH3, X=S, n=1; Ig: R1=OMe, X=S, n=1; Ih: R1=OMe, X=NCH3, n=1; Ii: R1=OMe, X=NCH3, n=2, where compounds If-Ii exhibit properties of fluorescent sensors on cations of alkali-earth, transition and heavy metals, and compounds Ia-Ie are intermediate compounds in the process of synthesis of compounds If-Ii. The invention also relates to a method of producing a compound of formula (I) and intermediate compounds of formula (II)
EFFECT: obtaining novel sensors on cations of alkali-earth, transition and heavy metals, novel methods of producing compounds of the given formula.
7 cl, 3 tbl, 7 ex
SUBSTANCE: invention relates to a novel cyclic carbodiimide compound of formula (i): (where X is any of divalent groups of formulae (i-1)-(i-3), or a tetravalent group of formula (i-4), when X is divalent, q equals 0, and when X is tetravalent, q equals 1, and each of Ar1-Ar4 independently denotes an aromatic group and can be substituted with an alkyl group containing 1-6 carbon atoms, or a phenyl group (i-1), where n is an integer from 1 to 6, (i-2), where each of m and n is independently an integer from 0 to 3, (i-3), where each of R1 and R2 is an alkyl group containing 1-6 carbon atoms, or a phenyl group , (i-4), which is useful as a polymer chain terminating agent, specifically an acid group capturing agent. Methods of obtaining a compound of formula (i) are also described.
EFFECT: improved properties of the compound.
10 cl, 10 ex
SUBSTANCE: invention relates to a compound of formula (A) or (B) where R1 is benzene, R2 is a hydrogen atom, R3 is independently selected from a group which includes a carboxyl group and carboxylate esters, X is a hydrogen atom, n is independently equal to 1-10, m=2, Y is independently selected from a group which includes a hydrogen atom, polystyrene and SiNH2, and Z is a hydrogen atom.
EFFECT: obtaining novel compounds which can be used to bind metals and/or elements of the main subgroup and removal thereof from liquids, solid substances, gases and/or fabric.
16 cl, 6 dwg, 22 ex, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is a pharmaceutical composition in the form of a spray for treating a damage by non-lethal irritants (e.g. pelargonic acid morpholide), containing pediphene in the following proportions, wt/volume %: pediphene hydrochloride 0.01-10.0; sodium chloride 0.1-10.0; water for injections up to 100 ml. What is shown is the efficacy of pediphene in compliance with the declared application ensured by the local anaesthetic effect of the drugs.
EFFECT: drug preparation has no allergenic and immunotoxic properties.
3 dwg, 40 tbl
SUBSTANCE: present invention relates to organic chemistry and medicine and specifically to a novel compound - 6-(thietanyl-3)aminopyrimidine-2,4(1H,3H)-dione of formula (1), which inhibits lipid peroxidation.
EFFECT: obtaining a compound which inhibits lipid peroxidation.
2 cl, 1 dwg, 2 ex
SUBSTANCE: copolymers of hetero-chain aliphatic poly-N-oxides of general formula (I) , where R=N, CH; x=2-4; y=0, 2; n=10-1000; q=(0.1-0.9)n; z=(0.1-0.9)n. Copolymers possess anti-oxidant action, therapeutic action as detoxicant and immunomodelling agent. Copolymers of formula (I) can be used as immunomodulating carrier for obtaining vaccinating medication and as carrier of medications for obtaining medications.
EFFECT: copolymers of hetero-chain aliphatic poly-N-oxides represent novel class of compounds possessing wide spectrum of pharmacological and vaccinating action, aimed at increase of safety in application, increase of technological and economical effectiveness and ecological safety of production of medications.
20 cl, 2 dwg, 13 tbl, 22 ex
SUBSTANCE: invention concerns animal breeding and veterinary. Method involves application of medicine. Chelavite microelement medication is used as preventive medicine in daily dosage of 0.2-0.4 ml per 10 kg of live weight perorally in the forage for constant application; daily dosage for treatment purposes comprises 0.6-0.8 ml per 10 kg of live weight for a month.
EFFECT: reduced lead and cadmium content in blood, milk and wool of animals, intoxication sign regress.
3 tbl, 2 ex
FIELD: medicine, toxicology.
SUBSTANCE: treatment is carried out for 2 steps wherein in the first step the preparation xydofone is administrated in the dose 10-20 mg per kg of body mass per 24 h by continuous course for 21-30 days, and in the second step the chelate-forming pharmaceutical preparation with the stability constant 15-20 is administrated in the therapeutic doses by fractional schedule for 2-7 days. Invention promotes to the complete elimination of heavy metal salts from the body due to weakly or strongly fixed ions of heavy metals providing by the successive administration of xydofone and the chelate-forming pharmaceutical preparation, and provides membrane-stabilizing effect on renal tissues that, in turn, prevents arising possible iatrogenic complications. Invention can be used in treatment of chronic intoxication with heavy metals.
EFFECT: improved and enhanced effectiveness of treatment.
3 cl, 2 tbl
FIELD: coordination compounds synthesis.
SUBSTANCE: invention provides complex comprising calcium and [[(4R)-4[bis[carboxy.kappa.O)methyl]amino-.kappa.N]-6,9-bis[carboxy-.kappa.O)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecane-11-ylic acid-.kappa.N6,.kappa.N9,-kappa.011]-oxydato(6-)]-,6H, (MS-325) or its salt with physiologically acceptable cation in each case containing essentially no Gf-MS-325. Also described are pharmaceutical agent based on compounds according to claim 1 and a method for preparing galena composition, complex or its salt with physiologically acceptable cation according to claim 1 intended for preparation of pharmaceutical agent reducing effect produced by heavy metals as well as complex or its salt with physiologically acceptable cation according to claim 1 intended for preparation of pharmaceutical agent suitable for NMR diagnostics and/or diagnostic radiology, a method for amplifying patient's image in NMR tomography based on compounds according to claim 1 and above defined complex or its salt with physiologically acceptable cation in each case containing essentially no visualizing metal chelates and MS-325.
EFFECT: increased assortment of complexes with useful medicine-destination properties.
14 cl, 4 dwg, 30 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a chemical compound of formula wherein R=benzyl and to an antituberculous therapeutic agent representing a composition of imidazo[1,2-b][1,2,4,5]tetrazine derivative of formula I, wherein R=benzyl, isopropyl or phenyl and the known antituberculous preparation pyrazinamide with the ingredients in mole ratio 1:1.
EFFECT: there are prepared new antituberculous therapeutic agents.
2 cl, 2 tbl, 6 ex
SUBSTANCE: in the process of obtaining microcapsules by a physical-chemical method of precipitation by means of a non-solvent, a heterocyclic compound is dissolved in DMSO, the obtained solution is transferred into a PVP water solution, the first precipitating agent - a mixture of acetic acid in acetone, containing octyl ether of acridonacetic acid (OeAAA) as SAS, is added, and after that, the second precipitating agent - a mixture of OeAAA in acetone is added, the obtained suspension is filtered, washed with acetone and dried.
EFFECT: realisation of the invention makes it possible to simplify the process of obtaining microcapsules and increase the output by weight.
SUBSTANCE: invention relates to field of veterinary and is intended for treatment and prevention of postpartum acute mastitis in cows. Medication contains antimicrobial, anti-inflammatory preparations and distilled water. Medication additionally contains licorice root. As antimicrobial preparation it contains metronidazole. as anti-inflammatory preparation it contains ciprofloxacin, with the following component ratio, g/l: licorice root 80-85 g; metronidazole 3.5-4.0 g; ciprofloxacin 2.0-2.5 g; distilled water - the remaining part.
EFFECT: application of claimed medication provides expressed antimicrobial and anti-inflammatory effect with simultaneous reduction of organism's response to histamine, release of spasm of smooth muscles and reduction of permeability of capillaries.
4 tbl, 10 ex
SUBSTANCE: present group of inventions refers to medicine, namely to therapy and virology, and concerns treating and preventing infectious diseases caused by an influenza virus with type H1N1 surface antigen. That is ensured by administering a therapeutic agent containing an active substance in the form of a homoeopathically activated potentiated form prepared by multiple serial dilution of a stock solution of affine purified antibodies to human gamma-interferon in a concentration of 0.3÷5.0 mg/ml.
EFFECT: administering this therapeutic agent provides effective treatment and prevention of the above infectious diseases.
6 cl, 4 ex, 1 tbl
SUBSTANCE: there are described new derivatives of imidazo[1,2-b][1,2,4,5]tetrazines of general formula (I) wherein: Het=4-methylimidazol-1-yl, R=H or Het=3,5-dimethylpyrazol-1-yl, R=propylthio, and based anticancer agents for treating oncological patients.
EFFECT: higher clinical effectiveness.
2 cl, 1 tbl, 2 ex
SUBSTANCE: after a colocolonic anastomosis is created 10-12 cm in a proximal direction from the anastomosis, a double tube is inserted into an intestinal lumen. After a transanal insertion of the tube, an infusion pump is used for dosed introduction of a rifaximin suspension at 0.01 mcg of an active substance per 1 kg of a patient's body weight a minute through one channel and a passive outflow through the second channel. The rifaximin suspension is introduced continuously for the first days, then 3 times a day for 3 hours until observing active intestinal peristalsis.
EFFECT: method provides effective prevention of colocolonic anastomotic leakage, reduces a probability of postoperative complications ensured by avoiding microbial contamination, infection and development of anastomositis, as well as promotes reducing the length of treatment and postoperative stay in hospital.
SUBSTANCE: rifabutin is dissolved in a water-miscible solvent which dissolves rifabutin better than water does; a rifabutin solution is prepared; gelatin is dissolved in water to prepare a gelatin solution; the rifabutin solution is slowly added to the gelatin solution while stirring to prepare a semi-product. The semi-product is dried in a spray drier or lyophilised to prepare a product. The prepared product is used as a part of a pharmaceutical composition for treating mycobacteriosis and Helicobacter pylori infection.
EFFECT: higher bioavailability of rifabutin.
46 cl, 8 tbl, 5 ex, 7 dwg
SUBSTANCE: invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, having physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterise butyrate.
EFFECT: novel compounds have an easily weighable form, are stable to acids and alkalis and are capable of releasing the acid in the small and large intestines continuously over a long time.
7 cl, 5 dwg, 15 ex